Home/Semax
Complete GuideRussia ApprovedBDNF + Neuroprotection

Semax:
Complete Research Guide

Full reference for the ACTH-derived cognitive enhancement peptide โ€” mechanism, Russian clinical data, NA Semax Amidate explained, and COA-verified vendor pricing.

๐Ÿงฌ Class Heptapeptide
โœ… Status Russia Approved
๐Ÿ“… Updated 2026
Jump toOverviewMechanismEvidenceProtocolPricing
โš ๏ธ

Research context only. Semax is approved in Russia. Not FDA-approved. Not medical advice.

Overview

Semax at a Glance

Structure
Heptapeptide (7 AA)
ACTH(4-7)-Pro-Gly-Pro; ACTH fragment extended for metabolic stability
Regulatory status
Approved in Russia
Stroke, cognitive impairment, ADHD. Not FDA-approved.
Primary effect
Cognitive enhancement
BDNF/NGF upregulation; dopaminergic and serotonergic enhancement
Key variant
NA Semax Amidate
N-acetylated and amidated for increased potency and stability
Mechanism

BDNF, NGF & Monoamines

Semax's most documented mechanism is rapid BDNF and NGF upregulation. Studies have shown significant increases in hippocampal and cortical BDNF within hours of intranasal administration. BDNF is essential for synaptic plasticity, long-term potentiation (the cellular basis of memory), and neuronal survival.

Simultaneously, Semax enhances dopaminergic and serotonergic neurotransmission in the prefrontal cortex โ€” the region responsible for working memory, executive function, and attention. This makes Semax's mechanism directly relevant to the cognitive processes most affected by ADHD, aging, and stress-induced impairment.

The neuroprotective effects are mechanistically distinct: anti-inflammatory (reduces microglial activation), antioxidant (reduces reactive oxygen species), and pro-survival signaling (PI3K/Akt pathway activation in ischemic conditions). These are the mechanisms underlying the Russian stroke approval.

Evidence

Research Summary

ApplicationEvidence LevelKey Findings
Cognitive enhancementRussian clinical trialsImproved attention, working memory, learning speed
Stroke / neuroprotectionRussian clinical approvalReduced neurological deficit post-stroke; faster recovery
BDNF upregulationWestern + RussianIndependently confirmed in multiple species and models
ADHD symptomsRussian trialsImproved attention and impulse control; not yet Western-validated
Optic nerve protectionRussian clinicalUsed for glaucoma-related optic neuropathy in Russia
Protocol

Research Protocol

ParameterBase SemaxNA Semax Amidate
Intranasal dose300โ€“900 mcg/day100โ€“600 mcg/day (more potent)
Frequency1โ€“2x daily1โ€“2x daily
Cycle10โ€“14 days on/off10โ€“14 days on/off
ReconstitutionBAC water, sterile saline, or water for injectionSame
Pricing

Verified Vendor Pricing

View Semax Pricing & Protocol

COA-verified vendor pricing with promo codes and reconstitution guide.

View Pricing โ†’ Dosage Calculator